BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 34403771)

  • 1. Advances in clinical immunotherapy for gastric cancer.
    Li K; Zhang A; Li X; Zhang H; Zhao L
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.
    Wu YX; Zhou XY; Wang JQ; Chen GM; Chen JX; Wang RC; Huang JQ; Chen JS
    Immunotherapy; 2023 Feb; 15(2):101-115. PubMed ID: 36597704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].
    Guo R; Li X; Hao M; Liang Y; Wang L; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1403-1424. PubMed ID: 37154314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
    Cheng R; Li B; Wang H; Zeng Y
    Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.
    Han Z; Zhang Z; Yang X; Li Z; Sang S; Islam MT; Guo AA; Li Z; Wang X; Wang J; Zhang T; Sun Z; Yu L; Wang W; Xiong W; Li G; Jiang Y
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38749538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers.
    Davern M; Lysaght J
    Cancer Lett; 2020 Dec; 495():89-99. PubMed ID: 32950619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers.
    Giorgione R; Risaliti M; Bartolini I; Rossi G; Pillozzi S; Muiesan P; Taddei A; Antonuzzo L
    Immunotherapy; 2022 May; 14(7):567-576. PubMed ID: 35382560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Immunotherapy in Triple-Negative Breast Cancer.
    Keenan TE; Tolaney SM
    J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of gastric cancer: Past, future perspective and challenges.
    Xie J; Fu L; Jin L
    Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of immune checkpoint inhibitors for gastric cancer.
    Kono K; Nakajima S; Mimura K
    Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of immunotherapy for advanced gastric cancer.
    Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
    Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
    Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
    World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
    Zhu ZG
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1331-1336. PubMed ID: 38644278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine signaling: Optimal target for gastric cancer immunotherapy.
    Wang J; Du L; Chen X
    Front Immunol; 2022; 13():1027838. PubMed ID: 36189223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in immune therapies for gastric cancer.
    Olnes MJ; Martinson HA
    Cancer Gene Ther; 2021 Sep; 28(9):924-934. PubMed ID: 33664460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
    Hotta K; Fujimoto N
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic advances in gastric cancer.
    Yoneda A; Kuroki T; Eguchi S
    Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.